Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

NCT06235190 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical study is to compare Felix NeuroAI Wristband and sham device in patients with essential tremor. The main question it aims to answer is: • Is Felix a safe and efficacious treatment for patients with essential tremor? Participants will be treated with either Felix or Sham for a period of up to 90 days. After that, they will be eligible to participate in a long-term, open-label study and be treated with Felix.

Conditions Studied

Interventions

  • DEVICE Sham Device
  • DEVICE Felix NeuroAI Wristband

Study Locations (12)

New York

  • Parkinson's Research Centers of America - Long Island — Commack
  • Columbia University Irving Medical Center — New York

Zhejiang

  • The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou
  • Sir Run Run Shaw Hospital — Hangzhou

Other

  • Xuanwu Hospital Capital Medical University — Beijing
  • Tianjin Medical University General Hospital — Tianjin

Arizona

  • Barrow Neurological Institute — Phoenix

California

  • Parkinson's Research Centers of America - Palo Alto — Palo Alto

Florida

  • Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton

Kansas

  • The University Of Kansas Medical Center — Kansas City

Ohio

  • University of Cincinnati — Cincinnati

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2024-02-27
Est. Completion 2025-11
Phase NA

Sponsor

Fasikl

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06235190

The ClinicalTrials.gov registry entry for NCT06235190 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fasikl, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Essential Tremor appearing as the primary indexed condition, and to 2 interventions — of which Sham Device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06235190 reports 12 study locations spanning 9 distinct geographic areas — top geographies include New York, Zhejiang, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06235190 about?

NCT06235190 is a clinical study titled "Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor". The goal of this clinical study is to compare Felix NeuroAI Wristband and sham device in patients with essential tremor. The main question it aims to answer is: • Is Felix a safe and efficacious treatment for patients with essential tremor? Participants will be treated with either Felix or Sham fo...

What is the current status of trial NCT06235190?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 126 participants. The study started on 2024-02-27. Estimated completion is 2025-11.

What conditions does trial NCT06235190 study?

This clinical trial studies the following conditions: Essential Tremor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06235190?

The interventions under investigation include: Sham Device (DEVICE), Felix NeuroAI Wristband (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06235190?

This trial is sponsored by Fasikl, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06235190 being conducted?

This trial has 12 study locations across Arizona, California, Florida, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial